Diagnostic utility of p63/P501S double sequential immunohistochemical staining in differentiating urothelial carcinoma from prostate carcinoma

Diagnostic Pathology

Volumn 6, Issue 1, 2011, Pages

  Srinivasan, Malini ^a   Parwani, Anil V ^b  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MEMBRANE PROTEIN; PROSTEIN; TP63 PROTEIN, HUMAN; TRANSCRIPTION FACTOR; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; CANCER GRADING; CARCINOMA; CHEMISTRY; DIFFERENTIAL DIAGNOSIS; EVALUATION; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; PATHOLOGY; PREDICTIVE VALUE; PROSTATE TUMOR; SENSITIVITY AND SPECIFICITY; UNITED STATES; URINARY TRACT CANCER; UROTHELIUM;

CARCINOMA; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MEMBRANE PROTEINS; NEOPLASM GRADING; PENNSYLVANIA; PREDICTIVE VALUE OF TESTS; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS; UROLOGIC NEOPLASMS; UROTHELIUM;

EID: 79960554117     PISSN: None     EISSN: 17461596     Source Type: Journal    
DOI: 10.1186/1746-1596-6-67     Document Type: Article

References (21)

1. Aihara M, Lebovitz RM, Wheeler TM, Kinner BM, Ohori M, Scardino PT. Prostate specific antigen and gleason grade: an immunohistochemical study of prostate cancer. J Urol 1994, 151:1558-1564.
2. Goldstein NS. Immunophenotypic characterization of 225 prostate adenocarcinomas with intermediate or high Gleason scores. Am J Clin Pathol 2002, 117:471-477. 10.1309/G6PR-Y774-X738-FG2K, 11888088.
3. Chuang AY, DeMarzo AM, Veltri RW, Sharma RB, Bieberich CJ, Epstein JI. Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma. Am J Surg Pathol 2007, 31:1246-1255. 10.1097/PAS.0b013e31802f5d33, 17667550.
4. Jiang Z, Fanger GR, Woda BA, Banner BF, Algate P, Dresser K, et al. Expression of alpha-methylacyl-CoA racemase (P504s) in various malignant neoplasms and normal tissues: astudy of 761 cases. Hum Pathol 2003, 34:792-796. 10.1016/S0046-8177(03)00268-5, 14506641.
5. Kalos M, Askaa J, Hylander BL, Repasky EA, Cai F, Vedvick T, et al. Prostein expression is highly restricted to normal and malignant prostate tissues. Prostate 2004, 60:246-256. 10.1002/pros.20043, 15176054.
6. Xu J, Kalos M, Stolk JA, Zasloff EJ, Zhang X, Houghton RL, et al. Identification and characterization of prostein, a novel prostate-specific protein. Cancer Res 2001, 61:1563-1568.
7. Hodges KB, Lopez-Beltran A, Emerson RE, Montironi R, Cheng L. Clinical utility of immunohistochemistry in the diagnoses of urinary bladder neoplasia. Appl Immunohistochem Mol Morphol 2010, 18:401-410.
8. Parker DC, Folpe AL, Bell J, Oliva E, Young RH, Cohen C, et al. Potential utility of uroplakin III, thrombomodulin, high molecular weight cytokeratin, and cytokeratin 20 in noninvasive, invasive, and metastatic urothelial (transitional cell) carcinomas. Am J Surg Pathol 2003, 27:1-10. 10.1097/00000478-200301000-00001, 12502922.
9. Ordonez NG. Thrombomodulin expression in transitional cell carcinoma. Am J Clin Pathol 1998, 110:385-390.
10. Kaufmann O, Volmerig J, Dietel M. Uroplakin III is a highly specific and moderately sensitive immunohistochemical marker for primary and metastatic urothelial carcinomas. Am J Clin Pathol 2000, 113:683-687. 10.1309/PYQC-17CB-063T-Q07J, 10800401.
11. Higgins JP, Kaygusuz G, Wang L, Montgomery K, Mason V, Zhu SX, et al. Placental S100 (S100P) and GATA3: markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray. Am J Surg Pathol 2007, 31:673-680. 10.1097/01.pas.0000213438.01278.5f, 17460449.
12. Di Como CJ, Urist MJ, Babayan I, Drobnjak M, Hedvat CV, Teruya-Feldstein J, et al. p63 expression profiles in human normal and tumor tissues. Clin Cancer Res 2002, 8:494-501.
13. Nekulova M, Holcakova J, Coates P, Vojtesek B. The role of p63 in cancer, stem cells and cancer stem cells. Cell Mol Biol Lett 2011, 16:296-327. 10.2478/s11658-011-0009-9, 21442444.
14. Varma M, Jasani B. Diagnostic utility of immunohistochemistry in morphologically difficult prostate cancer: review of current literature. Histopathology 2005, 47:1-16. 10.1111/j.1365-2559.2005.02188.x, 15982318.
15. Kunju LP, Mehra R, Snyder M, Shah RB. Prostate-specific antigen, high-molecular-weight cytokeratin (clone 34betaE12), and/or p63: an optimal immunohistochemical panel to distinguish poorly differentiated prostate adenocarcinoma from urothelial carcinoma. Am J Clin Pathol 2006, 125:675-681. 10.1309/V1RY91NKX5ARW2Q5, 16707367.
16. Sheridan T, Herawi M, Epstein JI, Illei PB. The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate. Am J Surg Pathol 2007, 31:1351-1355. 10.1097/PAS.0b013e3180536678, 17721190.
17. Yin M, Dhir R, Parwani AV. Diagnostic utility of p501s (prostein) in comparison to prostate specific antigen (PSA) for the detection of metastatic prostatic adenocarcinoma. Diagn Pathol 2007, 2:41. 10.1186/1746-1596-2-41, 2174437, 17963516.
18. Lane Z, Hansel DE, Epstein JI. Immunohistochemical expression of prostatic antigens in adenocarcinoma and villous adenoma of the urinary bladder. Am J Surg Pathol 2008, 32:1322-1326. 10.1097/PAS.0b013e3181656ca0, 18670358.
19. Farinola MA, Epstein JI. Utility of immunohistochemistry for alpha-methylacyl-CoA racemase in distinguishing atrophic prostate cancer from benign atrophy. Hum Pathol 2004, 35:1272-1278. 10.1016/j.humpath.2004.06.015, 15492996.
20. Osunkoya AO, Hansel DE, Sun X, Netto GJ, Epstein JI. Aberrant diffuse expression of p63 in adenocarcinoma of the prostate on needle biopsy and radical prostatectomy: report of 21 cases. Am J Surg Pathol 2008, 32:461-467. 10.1097/PAS.0b013e318157020e, 18300803.
21. Varma M, Morgan M, Amin MB, Wozniak S, Jasani B. High molecular weight cytokeratin antibody (clone 34betaE12): a sensitive marker for differentiation of high-grade invasive urothelial carcinoma from prostate cancer. Histopathology 2003, 42:167-172. 10.1046/j.1365-2559.2003.01560.x, 12558749.